GBT-201: Phase III started

ReGenTree LLC began a double-blind, placebo-controlled, U.S. Phase III trial to evaluate RGN-259 eye drops given 4 times daily for 28 days in about 500 patients. ReGenTree, a JV between RegeneRx and G...